National Institute of Allergy andInfectious Diseases (NIAID) http://www.niaid.nih.gov
FOR IMMEDIATE RELEASE
Friday, Oct. 8, 20048:00 a.m. Eastern Time
Scientists supported by the National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health, have discovered that people with chronic sinus inflammation have an exaggerated immune response to common airborne fungi. The results of their study appear online today in The Journal of Allergy and Clinical Immunology.
"This study is the first to show a possible immunologic basis for chronic sinusitis, an important starting point to better understand the etiology of the illness," says Marshall Plaut, M.D., chief of NIAID's allergic mechanisms section. Despite the enormous health impact of chronic sinusitis-nearly 30 million people were diagnosed with sinusitis in 2002, according to U.S. Centers for Disease Control and Prevention, and direct costs of the illness exceed $5.6 billion per year-the condition is very poorly understood, he says.
The researchers, led by Hirohito Kita, M.D., of the Mayo Clinic in Rochester, MN, compared blood samples taken from 18 people diagnosed with chronic sinusitis with blood samples from 15 healthy volunteers. Nasal secretions from the two groups were also examined for the presence of fungal proteins and inflammation-causing immune system molecules.
Airborne microscopic fungi spores abound indoors and out. People may inhale a million or more fungal spores each day, notes Dr. Kita. The mere presence of such fungi in the airways, however, is not enough to cause sinusitis because these spores can be found in the upper respiratory tracts of both sinusitis sufferers and non-sufferers. Indeed, in this study, levels of fungal proteins in nasal secretions were similar in both groups.
The Mayo Clinic scientists looked for evidence that people with sinusitis respond abnormally to these harmless fungi. The investigators exposed immune cells derived from the blood samples to extracts of four common airborne fungi: Alternaria, Aspergillus, Penicillium and Cladosporium. The cells of chronic sinusitis sufferers released significant amounts of three immune-modulating chemicals, called cytokines, specifically interferon-gamma, interleukin-5 (IL-5) and IL-13. In contrast, cells from healthy volunteers released very little interferon-gamma and no IL-5 or IL-13. The most dramatic responses occurred after exposure to Alternaria.
Importantly, says Dr. Kita, the released cytokines represent both major classes of cytokines-interferon-gamma is in the Th1 group and IL-5 and IL-13 are in the Th2 class. This is notable because scientists have thought that allergic reactions involve only Th2 cytokines, Dr. Kita explains. (While chronic sinusitis is not considered to be an allergic disease, people with the condition also often have asthma and allergic rhinitis, giving scientists reason to suspect a link.) The current findings add to an evolving understanding of allergic diseases that suggests symptoms may stem from a combination of Th1 and Th2 cytokines.
The combined effect of excess Th2 and Th1 cytokines released in the presence of fungi may explain a number of chronic sinusitis symptoms, including persistent inflammation of sinus and nasal mucous passages, say the scientists.
Previously, Mayo clinic scientists used intranasal antifungal agents to successfully treat patients with chronic sinusitis. While those studies generated controversy, in part because other researchers were unable to replicate the findings, Dr. Kita says today's report supports the rationale of treating chronic sinusitis with antifungals. Clinical trials to further test antifungal therapy for chronic sinusitis are being planned, adds Dr. Kita.
###References: S-H Shin et al. Chronic rhinosinusitis: An enhanced immune response to ubiquitous airborne fungi. The Journal of Allergy and Clinical Immunology. Published online Oct. 8, 2004. doi: 10.1016/j.jaci.2004.06.012.
S-H Shin et al. Chronic rhinosinusitis: An enhanced immune response to ubiquitous airborne fungi. The Journal of Allergy and Clinical Immunology. Published online Oct. 8, 2004. doi: 10.1016/j.jaci.2004.06.012.
NIAID conducts and supports research—at NIH, throughout the United States, and worldwide—to study the causes of
infectious and immune-mediated diseases, and to develop better means of preventing, diagnosing and treating these illnesses. News
releases, fact sheets and other NIAID-related materials are available on the NIAID Web site at www.niaid.nih.gov.
About the National Institutes of Health (NIH): NIH, the nation's medical research agency, includes 27 Institutes and Centers and is a component of the U.S.
Department of Health and Human Services. NIH is the primary federal agency conducting and supporting basic, clinical, and translational medical research,
and is investigating the causes, treatments, and cures for both common and rare diseases. For more information about NIH and its programs, visit www.nih.gov.
NIH...Turning Discovery Into Health ®
back to top
Last Updated October 08, 2004